The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor geno-typing as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer.

Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer.

Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.